A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clindamycin-B Isomer - Request Quote

Picture of Clindamycin-B Isomer

Clindamycin-B Isomer

SZ CAT No:SZ-C076088
CAS No
NA
Mol.F.
C17H31ClN2O5S
Mol.Wt.
411.0
Inv. Status
Under QC Approval

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Clindamycin-B Isomer is chemically (2S,4S)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-4-ethyl-1-methylpyrrolidine-2-carboxamide. Clindamycin-B Isomer is supplied with detailed characterization data compliant with regulatory guideline. Clindamycin-B Isomer can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Clindamycin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Clindamycin-B Isomer

Purchase Clindamycin-B Isomer

Clindamycin-B Isomer suppliers

Clindamycin-B Isomer manufacturers

Clindamycin-B Isomer price

Order Clindamycin-B Isomer

Enquire Clindamycin-B Isomer

Clindamycin-B Isomer cost

Clindamycin-B Isomer Supplier

Clindamycin-B Isomer Distributor

Clindamycin-B Isomer for Method Validation

Clindamycin Reference Standard

Clindamycin-B Isomer for ANDA Filing

Clindamycin-B Isomer for Forced Degradation Studies

Clindamycin-B Isomer Identification Standards

Clindamycin-B Isomer for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,